Skip to main content

Clenpiq Disease Interactions

There are 8 disease interactions with Clenpiq (citric acid/magnesium oxide/sodium picosulfate).

Major

Laxatives (applies to Clenpiq) inflammatory bowel disease

Major Potential Hazard, Moderate plausibility.

The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.

References

  1. (2001) "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc
  2. "Product Information. Fleet Bisacodyl (bisacodyl)." Fleet
  3. "Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb
  4. (2001) "Product Information. Neoloid (castor oil)." Paddock Laboratories Inc
  5. (2022) "Product Information. SenoSol-X (senna)." Apothecon Inc
  6. (2010) "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories
View all 6 references
Major

Laxatives (applies to Clenpiq) intestinal obstruction disorders

Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction

The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.

References

  1. (2001) "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc
  2. "Product Information. Fleet Bisacodyl (bisacodyl)." Fleet
  3. "Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb
  4. (2001) "Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet
  5. (2001) "Product Information. Citrucel (methylcellulose)." SmithKline Beecham
  6. (2001) "Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc
  7. (2022) "Product Information. SenoSol-X (senna)." Apothecon Inc
  8. (2010) "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories
View all 8 references
Major

Magnesium salts (applies to Clenpiq) renal dysfunction

Major Potential Hazard, High plausibility.

Magnesium is eliminated by the kidney. The serum concentration of magnesium is increased in patients with renal impairment. Magnesium toxicity includes CNS depression, muscular paralysis, respiratory depression, hypotension and prolonged cardiac conduction time. Disappearance of the patellar reflex is a useful clinical sign of magnesium intoxication. Therapy with magnesium should be administered cautiously and dosages should be modified in patients with compromised renal function. Clinical monitoring of serum magnesium levels is recommended.

References

  1. (2001) "Product Information. Mag-Ox 400 (magnesium oxide)." Blaine Company Inc.
  2. (2001) "Product Information. Uro-Mag (magnesium oxide)." Blaine Company Inc.
  3. (2001) "Product Information. Slow-Mag (magnesium chloride)." Searle
  4. (2001) "Product Information. Magonate (magnesium gluconate)." Fleming and Company
  5. (2001) "Product Information. Losospan (magaldrate)." Whitehall-Robbins
View all 5 references
Major

Sodium picosulfate (applies to Clenpiq) GI complications

Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction, Gastrointestinal Perforation

Sodium picosulfate is a stimulant laxative contraindicated in patients with gastrointestinal complications, such as gastrointestinal obstruction or ileus, bowel perforation, toxic colitis or toxic megacolon, and gastric retention.

References

  1. (2022) "Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate)." Ferring Pharmaceuticals Inc
Major

Sodium picosulfate (applies to Clenpiq) renal impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

The use of sodium picosulfate is contraindicated in patients with severe renal impairment (creatinine clearance less than 30 mL/min) as accumulation of magnesium in plasma may occur. Use caution in patients with mild to moderate renal impairment or patients taking concomitant medications that may affect renal function as these patients may be at increased risk for renal injury. It is recommended to assess baseline and post-colonoscopy laboratory tests (electrolytes, creatinine, and BUN) in these patients.

References

  1. (2022) "Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate)." Ferring Pharmaceuticals Inc
Moderate

Sodium picosulfate (applies to Clenpiq) arrhythmia

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Arrhythmias, Heart Disease, Electrolyte Abnormalities

The use of sodium picosulfate may cause serious arrhythmia. Use caution when prescribing this agent in patients at increased risk of arrhythmias (e.g., patients with a history of prolonged QT, uncontrolled arrhythmias, recent myocardial infarction, unstable angina, congestive heart failure, or cardiomyopathy). It is recommended to consider pre-dose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias.

References

  1. (2022) "Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate)." Ferring Pharmaceuticals Inc
Moderate

Sodium picosulfate (applies to Clenpiq) seizures

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Electrolyte Abnormalities

The use of sodium picosulfate may cause generalized tonic-clonic seizures. Use caution when using this agent in patients with a history of seizures and in patients at risk of seizure, such as patients taking medications that lower the seizure threshold (e.g., tricyclic antidepressants), patients withdrawing from alcohol or benzodiazepines, or patients with known or suspected electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, and hypomagnesemia) and low serum osmolality.

References

  1. (2022) "Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate)." Ferring Pharmaceuticals Inc
Moderate

Sodium picosulfate (applies to Clenpiq) ulcerative colitis

Moderate Potential Hazard, Moderate plausibility.

Osmotic laxatives may produce colonic mucosal aphthous ulcerations. Sodium picosulfate should be used with caution in patients with severe active ulcerative colitis. Appropriate diagnostic studies should be performed to rule out gastrointestinal obstruction or perforation before administering this agent.

References

  1. (2022) "Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate)." Ferring Pharmaceuticals Inc

Clenpiq drug interactions

There are 656 drug interactions with Clenpiq (citric acid/magnesium oxide/sodium picosulfate).

Clenpiq alcohol/food interactions

There is 1 alcohol/food interaction with Clenpiq (citric acid/magnesium oxide/sodium picosulfate).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.